Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 147

1.

Serum matrilysin levels predict outcome in curatively resected colorectal cancer patients.

Martínez-Fernandez A, García-Albeniz X, Pineda E, Visa L, Gallego R, Codony-Servat J, Augé JM, Longarón R, Gascón P, Lacy A, Castells A, Maurel J.

Ann Surg Oncol. 2009 May;16(5):1412-20. doi: 10.1245/s10434-009-0405-9. Epub 2009 Mar 4.

PMID:
19259740
2.

Clinicopathologic and prognostic significance of matrix metalloproteinases in rectal cancer.

Schwandner O, Schlamp A, Broll R, Bruch HP.

Int J Colorectal Dis. 2007 Feb;22(2):127-36. Epub 2006 Aug 2.

PMID:
16896992
3.

Prognostic significance of multiple molecular markers for patients with stage II colorectal cancer undergoing curative resection.

Uen YH, Lin SR, Wu DC, Su YC, Wu JY, Cheng TL, Chi CW, Wang JY.

Ann Surg. 2007 Dec;246(6):1040-6.

PMID:
18043108
4.

High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma.

Nikkola J, Vihinen P, Vuoristo MS, Kellokumpu-Lehtinen P, Kähäri VM, Pyrhönen S.

Clin Cancer Res. 2005 Jul 15;11(14):5158-66.

5.

Clodronate treatment influences MMP-2 associated outcome in node positive breast cancer.

Leppä S, Saarto T, Vehmanen L, Blomqvist C, Elomaa I.

Breast Cancer Res Treat. 2005 Mar;90(2):117-25.

PMID:
15803358
6.

Pre- and postoperative levels in serum of mannan-binding lectin associated serine protease-2 -a prognostic marker in colorectal cancer.

Ytting H, Christensen IJ, Thiel S, Jensenius JC, Nielsen HJ.

Hum Immunol. 2008 Jul;69(7):414-20. doi: 10.1016/j.humimm.2008.05.005. Epub 2008 Jun 11.

PMID:
18638656
7.

Preoperative serum vascular endothelial growth factor-a is a marker for subsequent recurrence in colorectal cancer patients.

Alabi AA, Suppiah A, Madden LA, Monson JR, Greenman J.

Dis Colon Rectum. 2009 May;52(5):993-9. doi: 10.1007/DCR.0b013e31819ed3bc.

PMID:
19502868
8.

Circulating gelatinases and tissue inhibitor of metalloproteinase-1 in colorectal cancer metastatic liver disease.

Waas ET, Wobbes T, Ruers T, Lomme RM, Hendriks T.

Eur J Surg Oncol. 2006 Sep;32(7):756-63. Epub 2006 May 2.

PMID:
16650961
9.

Serum matrix-metalloproteinase-1 is a bona fide prognostic marker for colorectal cancer.

Tahara K, Mimori K, Iinuma H, Iwatsuki M, Yokobori T, Ishii H, Anai H, Kitano S, Mori M.

Ann Surg Oncol. 2010 Dec;17(12):3362-9. doi: 10.1245/s10434-010-1149-2. Epub 2010 Jul 9.

PMID:
20617463
10.

Serum IGF-I, IGFBP-3, and matrix metalloproteinase-7 levels and acquired chemo-resistance in advanced colorectal cancer.

Gallego R, Codony-Servat J, García-Albéniz X, Carcereny E, Longarón R, Oliveras A, Tosca M, Augé JM, Gascón P, Maurel J.

Endocr Relat Cancer. 2009 Mar;16(1):311-7. doi: 10.1677/ERC-08-0250. Epub 2008 Dec 24.

11.

Circulating levels of VCAM and MMP-2 may help identify patients with more aggressive prostate cancer.

De Cicco C, Ravasi L, Zorzino L, Sandri MT, Botteri E, Verweij F, Granchi D, de Cobelli O, Paganelli G.

Curr Cancer Drug Targets. 2008 May;8(3):199-206.

PMID:
18473733
12.

The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer.

Riediger H, Keck T, Wellner U, zur Hausen A, Adam U, Hopt UT, Makowiec F.

J Gastrointest Surg. 2009 Jul;13(7):1337-44. doi: 10.1007/s11605-009-0919-2. Epub 2009 May 6.

PMID:
19418101
13.

Utility of serum preoperative carcinoemberyonic antigen in colorectal cancer patients.

El-Awady S, Lithy R, Morshed M, Khafagy W, Abd Monem H, Waleed O, Badr S, Fekry A, El Nakeeb A, Ghazy H, El Yamany M, Metwally T, El-Arman M, Farid M.

Hepatogastroenterology. 2009 Mar-Apr;56(90):361-6.

PMID:
19579599
14.

Plasma matrix metalloproteinase-9 level is better than serum matrix metalloproteinase-9 level to predict gastric cancer evolution.

Wu CY, Wu MS, Chiang EP, Chen YJ, Chen CJ, Chi NH, Shih YT, Chen GH, Lin JT.

Clin Cancer Res. 2007 Apr 1;13(7):2054-60.

15.

Matrix metalloproteinase-7 as a marker of metastasis and predictor of poor survival in bladder cancer.

Szarvas T, Becker M, vom Dorp F, Gethmann C, Tötsch M, Bánkfalvi A, Schmid KW, Romics I, Rübben H, Ergün S.

Cancer Sci. 2010 May;101(5):1300-8. doi: 10.1111/j.1349-7006.2010.01506.x. Epub 2010 Jan 20.

16.

Is C-reactive protein a prognostic factor of colorectal cancer?

Shiu YC, Lin JK, Huang CJ, Jiang JK, Wang LW, Huang HC, Yang SH.

Dis Colon Rectum. 2008 Apr;51(4):443-9. doi: 10.1007/s10350-007-9133-z. Epub 2008 Jan 3.

PMID:
18172726
17.

Serum p53 antibody as tumor marker for follow-up of colorectal cancer after curative resection.

Tang R, Yeh CY, Wang JY, Changchien CR, Chen JS, Hsieh LL.

Ann Surg Oncol. 2009 Sep;16(9):2516-23. doi: 10.1245/s10434-009-0578-2. Epub 2009 Jun 30.

PMID:
19565285
18.

MMP-9 (gelatinase B) expression is associated with disease-free survival and disease-specific survival in colorectal cancer patients.

Bendardaf R, Buhmeida A, Hilska M, Laato M, Syrjänen S, Syrjänen K, Collan Y, Pyrhönen S.

Cancer Invest. 2010 Jan;28(1):38-43. doi: 10.3109/07357900802672761.

PMID:
20001295
19.

Cellular localization of EMMPRIN predicts prognosis of patients with operable lung adenocarcinoma independent from MMP-2 and MMP-9.

Sienel W, Polzer B, Elshawi K, Lindner M, Morresi-Hauf A, Vay C, Eder F, Passlick B, Klein CA.

Mod Pathol. 2008 Sep;21(9):1130-8. doi: 10.1038/modpathol.2008.102. Epub 2008 Jun 20.

20.

[Prognostic significance and clinic utility of serum and immunohistochemical cathepsin B levels in colorectal cancer].

Padilla D, Cubo T, Molina JM, García M, De la Osa G, Palomino T, Pardo R, Martín J, Arévalo E, Hernández Calvo J.

An Med Interna. 2003 Oct;20(10):521-5. Spanish.

PMID:
14585038

Supplemental Content

Support Center